Which has better valuation and earnings, VTRS or LNTH?

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.36 -$3.51B -$0.36 N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.39

Is VTRS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Lantheus 17.69% 28.10% 14.35%

Does the media favor VTRS or LNTH?

In the previous week, Lantheus had 6 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Lantheus and 1 mentions for Viatris. Lantheus' average media sentiment score of 1.34 beat Viatris' score of 0.86 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or JAZZ?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Jazz Pharmaceuticals and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Jazz Pharmaceuticals' score of 0.40 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer LNTH or NBIX?

In the previous week, Neurocrine Biosciences had 11 more articles in the media than Lantheus. MarketBeat recorded 18 mentions for Neurocrine Biosciences and 7 mentions for Lantheus. Neurocrine Biosciences' average media sentiment score of 1.42 beat Lantheus' score of 1.34 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LNTH or CORT?

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.14 24.39 Corcept Therapeutics $761.41M 15.85 $99.65M $0.42 265.76

Does the media prefer LNTH or CORT?

In the previous week, Corcept Therapeutics had 9 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Corcept Therapeutics and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Corcept Therapeutics' score of 0.86 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or LNTH?

In the previous week, Elanco Animal Health had 9 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Elanco Animal Health and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Elanco Animal Health's score of 1.28 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 15 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantheus (LNTH) Competitors

$100.97 -0.01 (-0.01%)

As of 09/4/2026 04:00 PM Eastern

Compare

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Lantheus stock or one of its competitors? Lantheus's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Viatris has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 6 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Lantheus and 1 mentions for Viatris. Lantheus' average media sentiment score of 1.34 beat Viatris' score of 0.86 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Viatris shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.36	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Lantheus	17.69%	28.10%	14.35%

Viatris presently has a consensus price target of $17.50, suggesting a potential upside of 3.67%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.07%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Lantheus beats Viatris on 12 of the 15 factors compared between the two stocks.

How does Lantheus compare to Jazz Pharmaceuticals?

Lantheus (NASDAQ:LNTH) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Lantheus has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39
Jazz Pharmaceuticals	$4.27B	3.75	-$356.15M	$14.50	17.02

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Jazz Pharmaceuticals and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Jazz Pharmaceuticals' score of 0.40 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Jazz Pharmaceuticals has a net margin of 20.45% compared to Lantheus' net margin of 17.69%. Jazz Pharmaceuticals' return on equity of 33.97% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 7.07%. Jazz Pharmaceuticals has a consensus target price of $285.44, suggesting a potential upside of 15.65%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Jazz Pharmaceuticals beats Lantheus on 11 of the 17 factors compared between the two stocks.

How does Lantheus compare to Neurocrine Biosciences?

Lantheus (NASDAQ:LNTH) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lantheus presently has a consensus price target of $108.11, suggesting a potential upside of 7.07%. Neurocrine Biosciences has a consensus price target of $201.05, suggesting a potential upside of 29.17%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 11 more articles in the media than Lantheus. MarketBeat recorded 18 mentions for Neurocrine Biosciences and 7 mentions for Lantheus. Neurocrine Biosciences' average media sentiment score of 1.42 beat Lantheus' score of 1.34 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	13 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Lantheus. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39
Neurocrine Biosciences	$2.86B	5.53	$478.60M	$6.82	22.82

Neurocrine Biosciences has a net margin of 20.91% compared to Lantheus' net margin of 17.69%. Lantheus' return on equity of 28.10% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Summary

Neurocrine Biosciences beats Lantheus on 14 of the 17 factors compared between the two stocks.

How does Lantheus compare to Corcept Therapeutics?

Lantheus (NASDAQ:LNTH) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39
Corcept Therapeutics	$761.41M	15.85	$99.65M	$0.42	265.76

Lantheus has a net margin of 17.69% compared to Corcept Therapeutics' net margin of 6.52%. Lantheus' return on equity of 28.10% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Corcept Therapeutics	6.52%	8.26%	6.45%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Corcept Therapeutics had 9 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Corcept Therapeutics and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Corcept Therapeutics' score of 0.86 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Lantheus presently has a consensus price target of $108.11, indicating a potential upside of 7.07%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 23.78%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lantheus and Corcept Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Lantheus compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Lantheus has a net margin of 17.69% compared to Elanco Animal Health's net margin of -3.96%. Lantheus' return on equity of 28.10% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Lantheus	17.69%	28.10%	14.35%

Elanco Animal Health currently has a consensus price target of $29.09, suggesting a potential upside of 18.84%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.07%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Elanco Animal Health had 9 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Elanco Animal Health and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.34 beat Elanco Animal Health's score of 1.28 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	15 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.59	-$232M	-$0.41	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lantheus beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.59B	$12.29B	$7.27B	$12.92B
Dividend Yield	N/A	2.59%	2.54%	8.90%
P/E Ratio	24.39	787.21	272.43	25.42
Price / Sales	4.27	793.46	637.14	97.20
Price / Cash	15.81	92.18	77.39	52.28
Price / Book	5.02	12.47	12.85	6.17
Net Income	$233.56M	$2.82B	$3.47B	$349.50M
7 Day Performance	0.20%	3.91%	0.97%	-0.15%
1 Month Performance	-0.52%	6.17%	5.47%	1.02%
1 Year Performance	84.42%	9.88%	24.29%	14.50%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	3.9154 of 5 stars	$100.97 0.0%	$108.11 +7.1%	+87.6%	$6.59B	$1.54B	24.39	1,193	Positive News
VTRS Viatris	2.4274 of 5 stars	$16.54 +1.3%	$17.50 +5.8%	+63.4%	$18.75B	$14.30B	N/A	30,000
JAZZ Jazz Pharmaceuticals	4.2202 of 5 stars	$254.47 +0.1%	$272.89 +7.2%	+92.8%	$16.51B	$4.60B	17.55	2,890	Insider Trade
NBIX Neurocrine Biosciences	4.9397 of 5 stars	$153.04 +0.3%	$200.86 +31.2%	+10.9%	$15.51B	$2.86B	22.44	2,000	Positive News Analyst Forecast
CORT Corcept Therapeutics	4.0505 of 5 stars	$123.24 +0.8%	$138.17 +12.1%	+60.9%	$13.22B	$761.41M	293.44	300	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Summary

How does Lantheus compare to Corcept Therapeutics?

Summary

How does Lantheus compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Which has more volatility & risk, VTRS or LNTH?

Does the media favor VTRS or LNTH?

Do insiders and institutionals have more ownership in VTRS or LNTH?

Which has better valuation and earnings, VTRS or LNTH?

Is VTRS or LNTH more profitable?

Do analysts recommend VTRS or LNTH?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Do institutionals & insiders hold more shares of LNTH or JAZZ?

Which has more volatility and risk, LNTH or JAZZ?

Which has higher valuation & earnings, LNTH or JAZZ?

Does the media prefer LNTH or JAZZ?

Is LNTH or JAZZ more profitable?

Do analysts rate LNTH or JAZZ?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Do insiders & institutionals have more ownership in LNTH or NBIX?

Do analysts prefer LNTH or NBIX?

Which has more volatility & risk, LNTH or NBIX?

Does the media prefer LNTH or NBIX?

Which has stronger earnings and valuation, LNTH or NBIX?

Is LNTH or NBIX more profitable?

Summary

How does Lantheus compare to Corcept Therapeutics?

Which has better earnings and valuation, LNTH or CORT?

Is LNTH or CORT more profitable?

Do institutionals and insiders hold more shares of LNTH or CORT?

Does the media prefer LNTH or CORT?

Which has more volatility & risk, LNTH or CORT?

Do analysts rate LNTH or CORT?

Summary

How does Lantheus compare to Elanco Animal Health?

Is ELAN or LNTH more profitable?

Do analysts rate ELAN or LNTH?

Does the media prefer ELAN or LNTH?

Which has more risk and volatility, ELAN or LNTH?

Which has stronger earnings and valuation, ELAN or LNTH?

Do institutionals and insiders have more ownership in ELAN or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools